Teva must diversify away from Copaxone regardless of the generic threat and they know it. Nevertheless, even if Teva loses the patent case in court, odds for generic Copaxone to be approved without clinical trials are close to zero, imo, so this is still a few years away.
Market Data 
Markets 
AI
